The Organ Transplant Crisis
Every day in the United States, roughly 17 people die waiting for an organ transplant. The gap between supply and demand is enormous and growing. As of early 2025, more than 100,000 Americans are on the national transplant waiting list, and globally the shortage is far worse. In many countries, organized transplant systems barely exist, and patients with failing organs simply have no options.
The root of the problem is straightforward: donor organs are scarce. They must come from individuals who have died under specific circumstances that leave organs viable, and even then, the organs must be a close immunological match to the recipient to avoid rejection. The average wait time for a kidney in the United States exceeds five years. For many patients, that wait is too long.
This crisis has driven researchers to pursue one of the most ambitious goals in modern medicine: building functional replacement organs in the laboratory. The field spans tissue engineering, 3D bioprinting, stem cell biology, and xenotransplantation, and while fully lab-grown complex organs remain a future milestone, the progress made in recent years has been remarkable.
Tissue Engineering Basics
Tissue engineering is the discipline at the heart of the lab-grown organ effort. At its simplest, the approach involves three components: cells, scaffolds, and signals.
Cells are the building blocks. Researchers typically use stem cells, which have the ability to develop into many different cell types. Induced pluripotent stem cells (iPSCs) are particularly valuable. These are adult cells (often taken from a patient’s own skin or blood) that have been reprogrammed back into a stem cell state, meaning they can then be directed to become heart cells, liver cells, kidney cells, or virtually any other type. Because iPSCs can be derived from the patient who will receive the organ, they offer the tantalizing possibility of organs that are immunologically matched, eliminating the need for lifelong immunosuppressive drugs.
Scaffolds provide the structural framework on which cells grow. Think of a scaffold as the architectural blueprint and skeleton of an organ. Scaffolds can be made from biodegradable synthetic polymers, natural materials like collagen, or even decellularized organs, real organs from which all living cells have been stripped away, leaving behind only the extracellular matrix (the protein framework that gives an organ its shape and structure). Decellularized scaffolds are appealing because they preserve the intricate architecture of blood vessels, ducts, and chambers that would be extremely difficult to engineer from scratch.
Signals are the chemical and mechanical cues that guide cells to grow, divide, and differentiate into the right types in the right places. Growth factors, hormones, and even mechanical forces like stretching or fluid flow play critical roles. Bioreactors, specialized chambers that carefully control temperature, oxygen levels, nutrient flow, and mechanical stimulation, are used to provide these signals in a controlled environment, essentially mimicking the conditions inside the human body.
3D Bioprinting
One of the most exciting advances in the field is 3D bioprinting, which uses modified 3D printers to deposit layers of living cells and biomaterials (collectively called “bioink”) into precise three-dimensional structures. The concept is analogous to conventional 3D printing, but instead of plastic or metal, the printer works with living biological material.
3D bioprinting has already produced functional tissues in the laboratory. Skin grafts, cartilage, and bone segments have been printed and tested. In 2022, 3DBio Therapeutics made history when surgeons at the Microtia-Congenital Ear Institute implanted a 3D-printed ear, made from the patient’s own cartilage cells, into a woman born with a small and malformed ear. The ear was printed using the company’s AuriNovo technology and represented the first clinical application of a 3D-bioprinted implant made from a patient’s own tissue.
Researchers at several institutions have also printed miniature kidneys, livers, and hearts, though these remain far too small and simple for clinical use. The primary challenge is vascularization: creating the intricate networks of tiny blood vessels that supply oxygen and nutrients to every cell in a thick, complex organ. Without adequate blood supply, cells in the interior of a printed organ die within hours. Solving the vascularization problem is widely regarded as the single most important hurdle standing between current technology and full-size, functional printed organs.
Organoids: Miniature Organs in a Dish
While printing full-size organs remains a long-term goal, researchers have made impressive strides with organoids. Organoids are tiny, self-organizing, three-dimensional structures grown from stem cells that mimic the architecture and function of real organs. They range in size from a fraction of a millimeter to a few millimeters and can replicate key features of the brain, gut, kidney, liver, lung, and other organs.
Organoids are not yet suitable for transplantation. They lack blood vessels, are far too small, and do not replicate every function of a full organ. But they are extraordinarily useful for research. Brain organoids (sometimes called “mini-brains”) have been used to study neurological diseases like Zika virus infection and Alzheimer’s disease. Gut organoids have helped researchers understand inflammatory bowel disease. Tumor-derived organoids allow oncologists to test chemotherapy drugs on a patient’s own cancer tissue in a dish, potentially predicting which treatments will work before administering them to the patient.
As organoid technology improves, researchers envision “assembloids,” structures made by fusing multiple organoids together to model interactions between different tissues, and eventually scaling organoids up to sizes that could be therapeutically relevant.
Notable Achievements
The field of lab-grown organs has a growing list of milestones that demonstrate real clinical impact.
Bladders: In 2006, Dr. Anthony Atala and his team at the Wake Forest Institute for Regenerative Medicine reported the successful implantation of lab-grown bladders into patients with spina bifida. The bladders were constructed by seeding the patients’ own cells onto biodegradable scaffolds, culturing them in bioreactors, and then surgically implanting them. Several patients showed improved bladder function years after the procedure.
Tracheas: Tissue-engineered tracheas (windpipes) have been implanted in a small number of patients, though the field has been marked by both breakthroughs and controversy. Decellularized donor tracheas seeded with the recipient’s own stem cells have shown promise in select cases, but long-term outcomes have been mixed, and the approach remains experimental.
Skin: Lab-grown skin is one of the most mature products in the field. Companies like Organogenesis produce FDA-approved skin substitutes used to treat burn victims and patients with chronic wounds. These products typically consist of living human skin cells seeded onto a scaffold and are applied directly to wounds to promote healing.
Ears: The 3DBio Therapeutics ear implant mentioned earlier represents a significant clinical milestone for 3D bioprinting. The approach demonstrated that patient-derived cells could be expanded in the lab, printed into a complex three-dimensional shape, and successfully implanted with the body accepting the new tissue.
Xenotransplantation: Pig Organs as a Bridge
While lab-grown organs develop toward clinical readiness, another approach has surged forward: xenotransplantation, the transplantation of organs from one species to another. Pigs are the preferred donor species because their organs are similar in size to human organs, they breed rapidly, and they can be raised in controlled environments.
The central challenge of xenotransplantation has always been immune rejection. Pig cells carry sugar molecules on their surfaces that the human immune system recognizes as foreign, triggering immediate and violent rejection. Gene editing technologies, particularly CRISPR-Cas9, have changed this equation dramatically. Researchers can now knock out the pig genes responsible for these problematic sugar molecules and insert human genes that help the pig organ evade the human immune system.
In January 2022, surgeons at the University of Maryland transplanted a genetically modified pig heart into David Bennett, a patient with terminal heart failure who was ineligible for a human donor heart. Bennett survived for two months with the pig heart functioning, a result that, while ending in the patient’s death (complicated by a porcine virus found in the heart), demonstrated that a modified pig heart could sustain human circulation. Subsequent pig kidney transplants into living human recipients have shown more encouraging durability, with some patients maintaining function for months.
Companies like eGenesis and United Therapeutics are developing pigs with dozens of genetic modifications designed to make their organs maximally compatible with human recipients. If the approach proves safe and durable in ongoing trials, pig organs could dramatically alleviate the transplant shortage within the next decade.
The Vascularization Challenge and Other Hurdles
Building complex organs in the lab requires solving several interrelated problems. Vascularization remains the most formidable. A human kidney contains roughly one million functional units called nephrons, each supplied by an elaborate capillary network. Replicating this level of vascular complexity in an engineered organ is beyond current capabilities, though researchers are making progress using sacrificial printing techniques (where temporary channels are printed and then dissolved to leave behind hollow vessels) and self-assembling vascular networks grown from endothelial cells.
Immune rejection remains a concern even for organs built from a patient’s own cells. The scaffolds, biomaterials, and residual animal proteins used in tissue engineering can trigger immune responses. Ensuring that lab-grown tissues mature properly, developing not just the right cell types but the right cellular organization and connections, is another ongoing challenge.
Regulatory pathways for these novel therapies are still being defined. Lab-grown organs do not fit neatly into existing categories of drugs, devices, or biologics, and regulators in the United States, Europe, and Asia are working to develop frameworks that ensure safety without stifling innovation.
Current Clinical Trials and Future Outlook
As of 2025, clinical trials involving tissue-engineered products are underway for skin, cartilage, corneas, and blood vessels. Xenotransplantation trials for pig kidneys and hearts are progressing with cautious optimism. Several groups are pursuing bioprinted tissues for reconstructive surgery.
The long-term vision is transformative. Imagine a future where a patient diagnosed with kidney failure provides a blood sample, from which iPSCs are generated and directed to form kidney tissue on a printed scaffold, matured in a bioreactor, and implanted within weeks, a perfect immunological match requiring no donor and no immunosuppression. That future remains years or likely decades away for complex organs like kidneys, hearts, and lungs. But for simpler tissues like cartilage, skin, bladders, and blood vessels, the future is already here.
The convergence of stem cell biology, 3D bioprinting, gene editing, and computational modeling (including AI-driven design of scaffolds and growth factor protocols) is accelerating progress at a pace that surprises even researchers working in the field. The organ shortage is one of medicine’s most painful failures. The technologies emerging from labs around the world offer, for the first time, a credible path to solving it.